Georg Schauer, PhD, President of Acandis Inc., discusses the Company, its novel devices and targeting the US market for neurointervention in an interview with SmartTRAK at the Society of Neurointerventional Surgery (SNIS) 19th annual meeting held in Toronto, Canada July 25-26, 2022
To find out more about how Acandis plans to differentiate itself and compete in the US market, click on the following video recorded live at SNIS 2022. (11:30 min). A link to download the complete transcript of the interview is also provided below.
Anne Staylor here with BioMedGPS. Today I'm at the Society of NeuroInterventional Surgery annual meeting here in Toronto and I have the pleasure of speaking with Dr. Georg Schauer who was recently appointed CEO of Acandis Inc. in the United States.
Dr. Schauer, thank you for talking with me today.
Georg Schauer, PhD: Yeah. Hello. Thanks very much for having me.
Let's start by having you just give us a little background on Acandis and how it's evolved to where it is today.
GS: Absolutely. So Acandis, founded in 2006 by Dr. Andreas Schüßler and his wife Kirsi Schüßler, is a rapidly growing medical device company in the field of neurovascular intervention. We started very small, but by now we have 220 employees. We are established in over 60 countries with quite a large portfolio in the treatment of both ischemic and hemorrhagic stroke. It started out as a research and development company and the strong focus on research and development has never left us.
So in the field of hemorrhagic stroke, we are both present in stent-assisted coiling with our ACCLINO flex plus Stent, as well as in flow diversion with our DERIVO that has recently gone into its second generation, the DERIVO 2 and also a device we call ACCERO that's also for stent-assisted coiling. On the ischemic side, we have our unique ICAD treatment with our CREDO stent. It's a laser-cut stent with high radial force that is used in conjunction with the NeuroSpeed Balloon Catheter.
And what makes this treatment really unique and internationally is ...
To download the complete transcript of Acandis Inc.'s CEO Georg Schauer's interview "Targeting the US Market for Neurointervention" just click the button below.
SmartTRAK is a comprehensive, easy-to-use, business intelligence solution for the Life Sciences Industry that provides breaking updates on pertinent company news, potential treatments and guidance, international survey results, statistical analysis by country, studies, trial results, financial impact and more. All subscribers receive a Daily Updates email containing the latest need-to-know news curated by our expert analysts. It's the perfect way to start your day! If you would like to learn more about SmartTRAK, just click here.
